U.S. Food and Drug Administration Approves Gilead's Once-Daily HIV Pill Complera
August 11, 2011
The Food and Drug Administration (FDA) on Wednesday approved the once-daily pill Complera for patients not previously treated for HIV.
Complera, made by Gilead Sciences Inc., combines tenofovir/emtricitabine (Truvada) with rilpivirine (Edurant), a Johnson & Johnson drug that received FDA approval in May. The combination treatment will cost approximately $1,705 a month.
A statement by Gilead said the approval of Complera was supported by data from two 48-week, Phase III studies -- ECHO and THRIVE -- that compared rilpivirine to efavirenz (Sustiva), made by Bristol-Myers Squibb Co., in treatment-naive adults with HIV-1 infection. Most patients in the rilpivirine study arm received Truvada as well.
Gilead stressed consideration of the following before starting patients on Complera:
Further, Complera has boxed warnings concerning lactic acidosis/severe hepatomegaly with steatosis and post-treatment acute exacerbation of hepatitis B.
For more information, visit www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/HIVandAIDSActivities/ucm267592.htm.
Reuters Health Medical News
FDA Approves Complera (Edurant + Truvada), a Second "All-in-One" Option for First-Line HIV Treatment
This article was provided by U.S. Centers for Disease Control and Prevention. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update. Visit the CDC's website to find out more about their activities, publications and services.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)